Description: Invivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury (SCI). The company is developing a Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold for the implantation at the site of injury within a spinal cord contusion; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Boston Children's Hospital and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.
Home Page: www.invivotherapeutics.com
NVIV Technical Analysis
One Kendall Square
Cambridge,
MA
02139
United States
Phone:
617 863 5500
Officers
| Name | Title |
|---|---|
| Dr. Richard M. Toselli | Pres, CEO, Chief Medical Officer & Director |
| Mr. Richard C. Christopher | CFO & Treasurer |
| Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Member of Scientific Advisory Board |
| Dr. Joseph Philip Vacanti | Co-Founder |
| Mr. Jerome Gangitano | Sr. VP of Operations |
| Ms. Heather M. Hamel J.D. | Chief Legal Officer & Gen. Counsel |
| Dr. Louis Vaickus FACP, M.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3476 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2010-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |